Scott Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Scott Campbell has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Andres Forero-Torres
University of Alabama at Birmingham, Birmingham, Alabama
36 shared publications - Anna Maria Storniolo
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN
36 shared publications - Antonio C. Wolff
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
36 shared publications - Christopher B. Umbricht
Johns Hopkins University School of Medicine, Baltimore, MD
36 shared publications - James N. Ingle
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
36 shared publications - Kala Visvanathan
Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, USA
36 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening
Supplementary Figure from Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening
Supplementary Figure from Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening
Background:Human papillomavirus (HPV) testing is the cornerstone of cervical cancer screening, with outstanding sensitivity but only moderate specificity. We evaluated whether reflex testing for cancer biomarkers improves the sensitivity/specificity balance of screening.Methods:Cervical samples from women in Cape Town, South Africa, ages 30–65 years, were collected and tested with Xpert HPV and with real-time PCR to detect mRNA for cyclin-dependent kinase inhibitor 2A (CDKN2A), topoisomerase 2 alpha (TOP2A), and Ki67 (MKi67). Women with histologically confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+; 85 women without and 166 with HIV) and women with no cervical disease (331 without and 257 with HIV) were included.Results:When used as reflex tests after a positive HPV result, biomarkers discriminated well between women with and without CIN2+. The inclusion of both CDKN2A and MKi67 had the best performance, with area under the curve (AUC) of 0.9171 and 0.8734 in women without and with HIV, respectively. Although excellent, these performance parameters did not improve on an approach utilizing only HPV testing with more stringent cycle threshold cutoffs and HPV genotype selection, which achieved AUC of 0.9059 and 0.8705 in women without and with HIV, respectively.Conclusions:Biomarkers can be used as triage after positive HPV results but do not outperform an approach utilizing higher viral load cutoffs on selected high-risk genotypes.Impact:A screening approach using HPV testing alone can be more easily implemented at the point of care.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening
Background:Human papillomavirus (HPV) testing is the cornerstone of cervical cancer screening, with outstanding sensitivity but only moderate specificity. We evaluated whether reflex testing for cancer biomarkers improves the sensitivity/specificity balance of screening.Methods:Cervical samples from women in Cape Town, South Africa, ages 30–65 years, were collected and tested with Xpert HPV and with real-time PCR to detect mRNA for cyclin-dependent kinase inhibitor 2A (CDKN2A), topoisomerase 2 alpha (TOP2A), and Ki67 (MKi67). Women with histologically confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+; 85 women without and 166 with HIV) and women with no cervical disease (331 without and 257 with HIV) were included.Results:When used as reflex tests after a positive HPV result, biomarkers discriminated well between women with and without CIN2+. The inclusion of both CDKN2A and MKi67 had the best performance, with area under the curve (AUC) of 0.9171 and 0.8734 in women without and with HIV, respectively. Although excellent, these performance parameters did not improve on an approach utilizing only HPV testing with more stringent cycle threshold cutoffs and HPV genotype selection, which achieved AUC of 0.9059 and 0.8705 in women without and with HIV, respectively.Conclusions:Biomarkers can be used as triage after positive HPV results but do not outperform an approach utilizing higher viral load cutoffs on selected high-risk genotypes.Impact:A screening approach using HPV testing alone can be more easily implemented at the point of care.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Overall and within batch Coefficient of Variation for CM and each Gene.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Overall and within batch Coefficient of Variation for CM and each Gene.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Association between week 4 CM and disease status at first restaging after adjusting for CEA.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Association between week 4 CM and disease status at first restaging after adjusting for CEA.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Supplementary Figure 3 displays baseline CM level by disease status at first restaging.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Supplementary Figure 3 displays baseline CM level by disease status at first restaging.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Supplementary figure 5 displays time updated ROC curves for (A) CM level at week 8, (B) Change in CM level (Week8 – Week4) and (C) the Combination of week 8 CM level and Change in CM level (Week 8-Week 4) using linear discriminant analysis.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Supplementary figure 5 displays time updated ROC curves for (A) CM level at week 8, (B) Change in CM level (Week8 – Week4) and (C) the Combination of week 8 CM level and Change in CM level (Week 8-Week 4) using linear discriminant analysis.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Association between week 4 CM and disease status at first restaging after adjusting for CTC
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Association between week 4 CM and disease status at first restaging after adjusting for CTC
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Association between week 4 CM and disease status at first restaging after adjusting for CA27-29.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Association between week 4 CM and disease status at first restaging after adjusting for CA27-29.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Supplementary figure 4 displays time updates ROC curves for week 4 CM level using two additional methods (A) binary thresholding and (B) random forest.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Supplementary figure 4 displays time updates ROC curves for week 4 CM level using two additional methods (A) binary thresholding and (B) random forest.